Please assess the completion status of the following clinical trial:

Trial Title: REWORD-HF REverse WOrsening Renal Function in Decompensated Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~On admission (screening)~* Informed consent~* Age 18-80 years~* NYHA class III - IV~* Signs of pulmonary (pulmonary rales, and interstitial oedema or pleural effusion on chest Xray) and/or systemic congestion (pitting ankle oedema and enlarged liver or ascites and neck vein distension ≥ 7 cm) and weight gain ≥ 2 kg during the previous week~* Glomerular filtration rate ≥ 30 ml/min~* BNP increased \>400 pg/ml (diagnostic cut-off for ADCHF), as confirmatory diagnostic test)~  24 hours after admission (randomization)~* Persistent signs of pulmonary (pulmonary rales, interstitial oedema or pleural effusion on chest Xray) and/or systemic congestion (ankle oedema, enlarged liver or ascites, neck vein distension ≥ 7 cm)~* Serum creatinine or urine output criteria indicative of modified RIFLE (AKI: risk) class at least 1 (increase x 1.5 in serum creatinine or decrease \> 25% in GFR or urine output \< 0.5 ml/Kg/h for more than 6 hours) 29-30 during diuretic infusion~Exclusion criteria~* Chronic kidney disease stage 4-5 (GFR \< 30 ml/min)~* Acute coronary syndromes~* Systolic blood pressure \<90 mm Hg/need for intravenous inotropes~* Hematocrit \> 45%~* Unattainable venous access~* Contraindications to anticoagulation by heparin~* Systemic infection~* Heart transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Infusional drug treatment (Type: ACTIVE_COMPARATOR): Diuretics or diuretics plus fixed low dose dopamine infusion
- Ultrafiltration (Type: EXPERIMENTAL): Device: Ultrafiltration appliance Sessions of 8 h UF are conducted on 2 subsequent days in the first 48 hours after randomization; a third session is performed on day 3 in case of persistent congestion

Based on this trial design, predict the completion outcome and termination type (if applicable).